Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

Bullboard Posts

Post by statsman1on Jul 22, 2013 2:40am

313 Views

Post# 21621133

APO short positions higher as @July 15, 2013

Short Summary

Acasti Pharma Inc. ( APO )

As of	Short Volume	Change In Volume
15/Jul/2013	14,600	9,600
30/Jun/2013	5,000	1,800
15/Jun/2013	3,200	2,900
31/May/2013	300	-5,200
15/May/2013	5,500	300
30/Apr/2013	5,200	-90,900
15/Apr/2013	96,100	82,200
31/Mar/2013	13,900	9,900
15/Mar/2013	4,000	-26,500
28/Feb/2013	30,500	-38,700
15/Feb/2013	69,200	63,400
31/Jan/2013	5,800	0